(Q40859410)

24 September 2017

1 reference

title

Comprehensive patient evaluation for benign prostatic hyperplasia (English)

1 reference

24 September 2017

Jepsen JV

1

1 reference

24 September 2017

Bruskewitz RC

series ordinal

2

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 April 1998

1 reference

24 September 2017

1 reference

24 September 2017

volume

51

1 reference

24 September 2017

issue

4A Suppl

1 reference

24 September 2017

page(s)

13-18

1 reference

Pressure/cross-sectional area relations in the proximal urethra of healthy males. Part 1: Elastance and estimated pressure in the uninstrumented urethra

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

Pressure/cross-sectional area relations in the proximal urethra of healthy males. Part 2: Power generation during voluntary contraction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

Transurethral microwave thermotherapy versus transurethral resection for benign prostatic hyperplasia: preliminary results of a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

Comparison of AUA symptom index in unselected males and females between fifty-five and seventy-nine years of age

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

A Randomized, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic Hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

Using repeated measures of symptom score, uroflowmetry and prostate specific antigen in the clinical management of prostate disease. Benign Prostatic Hyperplasia Treatment Outcomes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

Reproducibility of uroflow measurement: experience during a double-blind, placebo-controlled study of doxazosin in benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

Reproducibility of pressure-flow variables in patients with symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

Variability and circadian changes in home uroflowmetry in patients with benign prostatic hyperplasia compared to normal controls.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

Prostatism and prostatectomy: the value of urine flow rate measurement in the preoperative assessment for operation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

In support of pressure-flow studies for evaluating men with lower urinary tract symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

Natural history of prostatism: worry and embarrassment from urinary symptoms and health care-seeking behavior.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

Do prostate size and urinary flow rates predict health care-seeking behavior for urinary symptoms in men?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

Urodynamics in prostatism. I. Prognostic value of uroflowmetry

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

Long-term predictive role of urodynamics: an 8-year follow-up of prostatic surgery for lower urinary tract symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

Transition zone volume and transition zone ratio: predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

Transition zone ratio and prostate-specific antigen density as predictors of the response of benign prostatic hypertrophy to alpha blocker and anti-androgen therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

Transition zone ratio and prostate-specific antigen density: the index of response of benign prostatic hypertrophy to an alpha blocker

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

The Assessment of Prostatic Obstruction from Urodynamic Measurements and from Residual Urine

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

Value of postvoid residual urine determination in evaluation of prostatism

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900050-8

7 January 2021

10.1016/S0090-4295(98)00050-8

Identifiers

DOI

1 reference

24 September 2017

1 reference